ข่าวประชาสัมพันธ์ Telmisartan

Telmisartan (MICARDIS(R)) as Effective as Ramipril but With Better Long-Term Tolerability in High-Risk Cardiovascular Asian Patients

New results from the landmark ONTARGET(R) Trial show that, in Asian patients at high risk of cardiovascular disease (CVD), telmisartan (MICARDIS(R)) 80mg is as effective as, and significantly better tolerated than, ramipril 10mg in reducing the risk of cardiovascular death, heart attack, stroke and hospitalisation for congestive heart failure.(1) These preliminary results were presented today at the 19th Great Wall -International Cardiology Congress (GW-ICC) in Beijing, China. Telmisartan and

24 ตุลาคม 2551 10:23 น.

First Landmark ARB Trial Against Placebo Shows MICARDIS(R) (Telmisartan) Reduces the Risk of Cardiovascular Death, Heart Attack and Stroke in ACE-Intolerant High-Risk Patients(1)

- TRANSCEND(R), Parallel Trial to ONTARGET(R), Confirms Long-Term Protective Benefits and Excellent Tolerability Profile... ก.ย. 51

MICARDIS(R)- Based Regimens Help More Patients Achieve Their Blood Pressure Goals

- New Studies Show Benefits of MICARDIS(R) (Telmisartan) in Combination With Amlodipine and Hydrochlorothiazide The results of two new studies of MICARDIS(R) (telmisartan) in free combination with amlodipine or fixed... มิ.ย. 51

Landmark Trial ONTARGET(R) Proves Telmisartan is as Protective as Ramipril and Better Tolerated in a Broad High-Risk Cardiovascular Population

- From ONTARGET(R) it May be Concluded That Telmisartan can Prevent Every 5th Serious Cardiovascular Event - Results of 25,620 Patient Study ONTARGET(R) ... เม.ย. 51

More Than Half of Hypertensive Patients Remain Uncontrolled and at Higher Risk of Heart Attack and Stroke - Telmisartan May Decrease This Risk

- Results From Two Large, Multinational, Practice-Based Observational Studies in Blood Pressure New data announced today at the Annual European Society of... มิ.ย. 50

New Study Shows That Telmisartan Has Greater Renoprotective Potential Than Losartan in Hypertensive Patients with Type 2 Diabetes

Today AMADEO, one of the first studies to compare the protective potential of two angiotensin receptor blockers in hypertensive patients with diabetic nephropathy, was... มิ.ย. 50

ASIANET: Boehringer เผยการทดลองรักษาโรคหัวใจสำหรับผู้ป่วยที่แพ้ยา ACE

บริษัท Boehringer Ingelheim ประกาศแผนจัดการทดลอง TRANSCEND ซึ่งเป็นตัวย่อของ Telmisartan Randomized AssessmeNt Study in aCE iNtolerant subjects with cardiovascular Disease และเป็นการทดลองวิธีการป้องกันโรคหัวใจครั้ง... มิ.ย. 44

ASIANET: Worldwide Study to Evaluate New Approach

Worldwide Study to Evaluate New Approach to Preventing Cardiovascular Disease in Ace Inhibitor-Intolerant Patients - Largest Cardiovascular Protection Trial Ever Conducted in This Patient Population Will Parallel Landmark 'ONTARGET' Study - MILAN,... มิ.ย. 44

ASIANET: ONTARGET ศึกษาผู้ป่วย 28,000 คนสำหรับการป้องกันโรคหัวใจ

บริษัท Boehringer Ingelheim ประกาศในวันนี้เกี่ยวกับแผนการจัดการทดลองทั่วโลกอย่างต่อเนื่อง ในชื่อ ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) ซึ่งเป็นการทดลองการใช้ telmisartan ทั้งในแบบใช้... มี.ค. 44

ASIANET: Landmark Worldwide 'ONTARGET' Study of Approximately 28,000 Patients

Landmark Worldwide 'ONTARGET' Study of Approximately 28,000 Patients to Evaluate the Role of a New Therapeutic Approach In Prevention Of Cardiovascular Disease Study at Up to 700 Sites Will Build On Landmark Hope Trial... มี.ค. 44